Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 6Nausea 3Neoplasms 2Uterine Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 4Leucovorin 4Irinotecan 4Fluorouracil 4Capecitabine 3Bevacizumab 3cobimetinib 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Panitumumab 2Magnetic Resonance Spectroscopy 2Ketamine 2Hydroxychloroquine 2Cyclophosphamide 2Cisplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sodium thiosulfate 1rucaparib 1romiplostim 1rilotumumab 1regorafenib 1pralsetinib 1ponatinib 1pembrolizumab 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Neoplasms × fosaprepitant × Clear all
NCT01504711 2021-04-08

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
30 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡